Skip to main content

Table 4 The association between rs2239647 and glioma patient OS and PFS

From: Impact of AKAP6 polymorphisms on Glioma susceptibility and prognosis

rs2239647GenotypeOSPFS
Log-rank pSR (1−/3-year)HR (95%CI)pLog-rank pSR (1−/3-year)HR (95%CI)p
 CC0.2270.328/0.0801.00 0.4130.182/0.0841.00 
CA0.327/0.1341.15 (0.86–1.54)0.3460.193/0.1221.13 (0.84–1.51)0.424
AA0.224/0.0340.91 (0.76–1.10)0.3250.138/0.0390.94 (0.78–1.13)0.517
Low-grade glioma(I–II)
 CC0.1240.324/0.0771.00 0.2670.159/−1.00 
CA0.349/0.1650.96 (0.66–1.39)0.8180.232/0.1470.93 (0.64–1.35)0.686
AA0.270/−0.80 (0.64–1.01)0.0650.189/−0.84 (0.66–1.06)0145
High-grade glioma (III–IV)
 CC0.0560.333/0.0851.00 0.0450.219/0.0921.00 
CA0.279/−1.61 (1.04–2.66)0.0350.106/−1.67 (1.04–2.67)0.034
AA0.143/−1.19 (0.87–1.63)0.2680.048/−1.21 (0.88–1.66)0.233
  1. OS Overall survival, PFS Progression free survival, SR Survival rate, HR Hazard ratio, 95% CI 95% Confidence interval
  2. Log-rank p values were calculated using the Chi-Square test
  3. Bold values indicate statistical significance (p < 0.05)